Ingalls & Snyder LLC Increased Its Corcept Therapeutics INC (CORT) Stake by $15.14 Million as Shares Declined

Corcept Therapeutics Incorporated (NASDAQ:CORT) Corporate LogoBig Money Sentiment decreased to 1.11 in Q3 2018. It has change of 0.07, from 2018Q2’s 1.18. The ratio dropped due to CORT positioning: 29 sold and 52 reduced. 24 funds bought holdings and 66 increased holdings. Investors holded 85.22 million in 2018Q2 but now own 86.70 million shares or 1.74% more. Great West Life Assurance Communications Can invested in 127,166 shs. Wealth Architects Ltd Liability Corporation holds 0.07% or 15,860 shs. Tudor Inv Corp Et Al accumulated 26,500 shs. Guggenheim Capital Ltd Liability Com, a Illinois-based fund reported 106,778 shs. State Of Alaska Department Of Revenue has invested 0.01% of its capital in Corcept Therapeutics Incorporated (NASDAQ:CORT). Quantitative Invest Mgmt Limited Liability Company has invested 0.01% in Corcept Therapeutics Incorporated (NASDAQ:CORT). Ameritas Invest Partners stated it has 0.01% in Corcept Therapeutics Incorporated (NASDAQ:CORT). First Ltd Partnership has 0% invested in Corcept Therapeutics Incorporated (NASDAQ:CORT) for 76,108 shs. Ami Asset Mngmt Corporation owns 629,361 shs or 0.6% of their US capital. Moreover, Profund Ltd has 0.02% invested in Corcept Therapeutics Incorporated (NASDAQ:CORT) for 43,464 shs. Blair William Com Il holds 27,000 shs. 20,000 were accumulated by Buckingham Asset Mgmt Limited Liability Co. Ny State Common Retirement Fund invested in 108,600 shs or 0% of the stock. Creative Planning reported 38,246 shs stake. Birchview Cap LP holds 50,000 shs or 0.45% of its capital.

CORT had 6 selling transactions and 4 insider buys since August 14, 2018. This’s net activity of $775,497. On Friday, September 7 $116,533 worth of stock was sold by FISHMAN ROBERT S. BELANOFF JOSEPH K sold $4.13 million worth of Corcept Therapeutics Incorporated (NASDAQ:CORT) on Wednesday, December 12. Robb Gary Charles also sold $475,153 worth of Corcept Therapeutics Incorporated (NASDAQ:CORT) shs. On Wednesday, December 12 the insider Maduck Sean sold $1.14 million.

The stake In Corcept Therapeutics Inc (CORT) was upped held by Ingalls & Snyder Llc. According to 2018Q3 Securities and Exchange form the decrease is 14.78%. By buying 1.08 million shares Ingalls & Snyder Llc made the stock sank with 10.36%. At the end of 2018Q3, the 8.40 million shares of the major pharmaceuticals company held by the institutional investor were priced at $117.74 million, up from 7.32 million at the end of the previous reported quarter. Ingalls & Snyder Llc has cut its stake in Corcept Therapeutics Inc (Call) (NASDAQ:CORT) and also reduced its holding in Canadian Nat Res Ltd (Call) (NYSE:CNQ) by 2.26 million shares in the quarter, for a total of 34,700 shares.

For more Corcept Therapeutics Incorporated (NASDAQ:CORT) news released briefly go to:,,, or The titles are as follows: “Corcept Therapeutics Announces Positive Relacorilant Data at the 2018 American Society of Clinical Oncology Meeting – GlobeNewswire” released on June 04, 2018, “Corcept Therapeutics Announces Third Quarter 2018 Financial Results and Provides Corporate Update – GlobeNewswire” on November 01, 2018, “Reader Inquiry: What’s In Store For Corcept Therapeutics? – Seeking Alpha” with a publish date: May 21, 2018, “BCS, SBS among premarket gainers – Seeking Alpha” and the last “Corcept medical chief to depart – Seeking Alpha” with publication date: November 19, 2018.

Corcept Therapeutics Incorporated (NASDAQ:CORT) Ratings Coverage

Total analysts of 2 have positions in Corcept Therapeutics (NASDAQ:CORT) as follows: 2 rated it a “Buy”, 0 with “Sell” and 0 with “Hold”. The positive are 100%. Since August 13, 2018 according to StockzIntelligence Inc Corcept Therapeutics has 3 analyst reports. On Monday, August 13 the rating was maintained by FBR Capital with “Buy”. The stock rating was upgraded by Cantor Fitzgerald to “Overweight” on Wednesday, December 12.

Corcept Therapeutics Incorporated (NASDAQ:CORT) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.